Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Just sent to JT:

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Biobillionair Member Profile
 
Followed By 105
Posts 15,417
Boards Moderated 0
Alias Born 01/12/13
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 5/23/2019 5:02:53 PM
Vascepa® to Be Featured in Multiple Scientific Sessions at the National Lipid Association Annual Meeting GlobeNewswire Inc. - 5/16/2019 4:15:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/1/2019 6:50:57 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/1/2019 6:49:35 AM
Amarin Reports First Quarter 2019 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 5/1/2019 5:00:00 AM
New Drug Submission Filed for Vascepa® with Health Canada GlobeNewswire Inc. - 4/29/2019 6:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/25/2019 7:02:14 AM
Amarin To Report First Quarter 2019 Results and Host Conference Call On May 1, 2019 GlobeNewswire Inc. - 4/24/2019 6:00:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/15/2019 5:08:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/1/2019 5:09:07 PM
Vascepa® Granted Priority Review Status from Health Canada GlobeNewswire Inc. - 3/29/2019 5:45:15 PM
Amarin Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for Vascepa® (icosapent ethyl) t... GlobeNewswire Inc. - 3/28/2019 4:51:57 PM
New Updates to the American Diabetes Association’s® 2019 Standards of Medical Care in Diabetes Incorporate Findings from t... GlobeNewswire Inc. - 3/28/2019 5:00:00 AM
Cardiovascular Risk at Multiple Triglyceride Thresholds Highlighted in Presentation at American College of Cardiology’s 68... GlobeNewswire Inc. - 3/19/2019 6:00:00 AM
Additional Real-World Data Show a Significant Risk Increase in Cardiovascular Events in People with Elevated Triglyceride Lev... GlobeNewswire Inc. - 3/18/2019 4:15:00 PM
Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™ PR Newswire (US) - 3/18/2019 9:00:00 AM
High Risk of Atherosclerotic Cardiovascular Events Projected in People with Elevated Triglycerides Without Established Athero... GlobeNewswire Inc. - 3/16/2019 5:30:00 PM
Investor Expectations to Drive Momentum within Amarin, PulteGroup, LivaNova, Teva Pharmaceutical Industries, Viad, and Activi... GlobeNewswire Inc. - 3/6/2019 8:25:00 AM
Amarin to Present at Cowen’s 39th Annual Health Care Conference GlobeNewswire Inc. - 3/5/2019 6:00:00 AM
Important New Data on Vascepa® (Icosapent Ethyl) from the REDUCE-IT™ Trial to Be Presented Regarding Reduction in Total Is... GlobeNewswire Inc. - 3/4/2019 4:30:00 PM
Gibbs Law Group Has Filed Sole Class Action; Shareholders Should Contact the Firm About Their Rights Business Wire - 3/1/2019 5:00:00 PM
The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amarin Corp. plc & En... Business Wire - 2/27/2019 2:25:00 PM
Annual Report (10-k) Edgar (US Regulatory) - 2/27/2019 6:39:33 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/27/2019 6:31:09 AM
Amarin Reports Record Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 2/27/2019 5:00:00 AM
Biobillionair   Tuesday, 02/12/19 09:33:51 AM
Re: None
Post # of 193541 
Just sent to JT:

Quote:
Hi John-

Just in case you haven’t seen the warning letters the FDA has recently sent, here’s a link: https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm630564.htm

Specifically relevant to Amarin and Vascepa quote:

On the webpage titled, “Omega 3 Benefits Stroke – Fish Oil Supplement May Help”:
Fish oil supplements have been shown to have anti-inflammatory effects in diseases such as cancer, asthma, rheumatoid arthritis, osteoporosis, dry eye disease, age-related macular degeneration, coronary heart disease and sepsis.”
“The use of fish oil supplements as a protective factor against stroke and other neurological diseases such as Alzheimer’s has been suggested.”


Hopefully we see the Federal Circuit Court FINALLY publish their ITC opinion, but the above should be reassuring from a legal stance the sNDA for REDUCE-IT won’t be used and abused by the supplement industry.

I look forward to watching you bring this home, and great job with the recent execution of raising cash and hiring sales. If the FDA doesn’t grant an accelerated approval I will obviously lose my shit, but there’s no blaming Amarin, you’ve put up a great fight.

Keep up the good work and please send a thank you to your leadership team.

Best Regards,

Jason



I have no information regarding when an sNDA will be filed, but it's one symbolic message if Amarin deliveries it Thursday 2-14-2019.

BB

I do not pump Amarin stock. I am not an Amarin cheerleader. If I see something I don't like I make it known. Patients come first, always!!!
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist